Shares of PureCycle Technologies, Inc. (NASDAQ:PCT – Get Free Report) dropped 4.7% during mid-day trading on Monday . The company traded as low as $12.22 and last traded at $12.27. Approximately 477,234 shares were traded during trading, a decline of 80% from the average daily volume of 2,341,998 shares. The stock had previously closed at $12.87.
Analyst Ratings Changes
PCT has been the topic of several recent analyst reports. TD Cowen lifted their target price on shares of PureCycle Technologies from $7.50 to $10.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Craig Hallum lifted their target price on shares of PureCycle Technologies from $4.00 to $6.00 and gave the stock a “hold” rating in a research report on Friday, August 9th. Stifel Nicolaus lifted their price target on shares of PureCycle Technologies from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, Cantor Fitzgerald started coverage on shares of PureCycle Technologies in a report on Friday, October 18th. They issued an “overweight” rating and a $14.00 price target on the stock. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $8.20.
Get Our Latest Stock Analysis on PCT
PureCycle Technologies Price Performance
PureCycle Technologies (NASDAQ:PCT – Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.13). Research analysts forecast that PureCycle Technologies, Inc. will post -0.98 earnings per share for the current year.
Insider Buying and Selling
In other PureCycle Technologies news, major shareholder Sylebra Capital Llc purchased 4,264,393 shares of the stock in a transaction on Friday, September 13th. The stock was acquired at an average cost of $4.69 per share, with a total value of $20,000,003.17. Following the completion of the purchase, the insider now directly owns 33,050,456 shares of the company’s stock, valued at approximately $155,006,638.64. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 11.44% of the stock is owned by company insiders.
Hedge Funds Weigh In On PureCycle Technologies
Several hedge funds and other institutional investors have recently modified their holdings of PCT. Ensign Peak Advisors Inc purchased a new stake in PureCycle Technologies in the second quarter worth about $311,000. Abundance Wealth Counselors lifted its holdings in PureCycle Technologies by 6.0% in the second quarter. Abundance Wealth Counselors now owns 7,189,490 shares of the company’s stock worth $42,562,000 after buying an additional 407,353 shares during the period. Longview Asset Management LLC purchased a new stake in PureCycle Technologies in the second quarter worth about $57,521,000. Marshall Wace LLP purchased a new stake in PureCycle Technologies in the second quarter worth about $322,000. Finally, Sanctuary Advisors LLC purchased a new stake in PureCycle Technologies in the second quarter worth about $689,000. 63.01% of the stock is owned by institutional investors.
PureCycle Technologies Company Profile
PureCycle Technologies, Inc engages in the production of recycled polypropylene (PP). The company holds a license for restoring waste PP into ultra-pure recycled polypropylene resin that has multiple applications, including packaging and labeling for consumer products, piping, ropes, cabling, and plastic parts for various industries.
Read More
- Five stocks we like better than PureCycle Technologies
- What is the S&P 500 and How It is Distinct from Other Indexes
- Intel: Is Now the Time to Be Brave?
- What is the Dogs of the Dow Strategy? Overview and Examples
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for PureCycle Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureCycle Technologies and related companies with MarketBeat.com's FREE daily email newsletter.